|
TM9SF2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.45170000359829E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.86210000050625E-07 |
| Normal-vs-Stage2 |
1.622130E-03 |
| Normal-vs-Stage3 |
3.03860003825207E-09 |
| Normal-vs-Stage4 |
3.97810000052345E-07 |
| Stage1-vs-Stage2 |
7.631800E-01 |
| Stage1-vs-Stage3 |
9.854400E-02 |
| Stage1-vs-Stage4 |
2.065600E-01 |
| Stage2-vs-Stage3 |
2.156400E-01 |
| Stage2-vs-Stage4 |
2.506000E-01 |
| Stage3-vs-Stage4 |
9.725000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.74389996571756E-09 |
| Normal-vs-AfricanAmerican |
8.657500E-03 |
| Normal-vs-Asian |
1.72474999999839E-05 |
| Caucasian-vs-AfricanAmerican |
2.507600E-01 |
| Caucasian-vs-Asian |
8.996200E-01 |
| AfricanAmerican-vs-Asian |
2.815000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.17189999926381E-08 |
| Normal-vs-Female |
3.4566999995711E-07 |
| Male-vs-Female |
1.317650E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.73270000000969E-06 |
| Normal-vs-Age(41-60Yrs) |
2.5314999996251E-07 |
| Normal-vs-Age(61-80Yrs) |
9.89600001943813E-09 |
| Normal-vs-Age(81-100Yrs) |
5.243100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.277400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.494550E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.583600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.739600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.449400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.467800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.904100E-02 |
| Classical-VS-Follicular |
5.578200E-01 |
| Classical-VS-Other |
8.265700E-02 |
| Classical-VS-Normal |
4.51020000014069E-07 |
| Tall-VS-Follicular |
2.033400E-01 |
| Tall-VS-Other |
3.361400E-01 |
| Tall-VS-Normal |
3.37929999982833E-07 |
| Follicular-VS-Other |
2.411600E-01 |
| Follicular-VS-Normal |
2.07459999999049E-05 |
| Other-VS-Normal |
3.448700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.9190999994988E-07 |
| Normal-vs-N1 |
5.2445000009449E-08 |
| N0-vs-N1 |
1.049010E-01 |
|
|
